These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

54 related items for PubMed ID: 1255491

  • 1. The development of new iron-chelating drugs.
    Grady RW, Graziano JH, Akers HA, Cerami A.
    J Pharmacol Exp Ther; 1976 Feb; 196(2):478-85. PubMed ID: 1255491
    [Abstract] [Full Text] [Related]

  • 2. The development of new iron-chelating drugs. II.
    Grady RW, Graziano JH, White GP, Jacobs A, Cerami A.
    J Pharmacol Exp Ther; 1978 Jun; 205(3):575-65. PubMed ID: 660531
    [Abstract] [Full Text] [Related]

  • 3. Rhodotorulic acid--investigation of its potential as an iron-chelating drug.
    Grady RW, Peterson CM, Jones RL, Graziano JH, Bhargava KK, Berdoukas VA, Kokkini G, Loukopoulos D, Cerami A.
    J Pharmacol Exp Ther; 1979 Jun; 209(3):342-8. PubMed ID: 108388
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of polymeric hydroxamic acid iron chelators for treatment of iron overload.
    Winston A, Varaprasad DV, Metterville JJ, Rosenkrantz H.
    J Pharmacol Exp Ther; 1985 Mar; 232(3):644-9. PubMed ID: 3973822
    [Abstract] [Full Text] [Related]

  • 5. The identification of 2, 3-dihydroxybenzoic acid as a potentially useful iron-chelating drug.
    Graziano JH, Grady RW, Cerami A.
    J Pharmacol Exp Ther; 1974 Sep; 190(3):570-5. PubMed ID: 4416298
    [No Abstract] [Full Text] [Related]

  • 6. The selection and evaluation of new chelating agents for the treatment of iron overload.
    Pitt CG, Gupta G, Estes WE, Rosenkrantz H, Metterville JJ, Crumbliss AL, Palmer RA, Nordquest KW, Hardy KA, Whitcomb DR, Byers BR, Arceneaux JE, Gaines CG, Sciortino CV.
    J Pharmacol Exp Ther; 1979 Jan; 208(1):12-8. PubMed ID: 759605
    [Abstract] [Full Text] [Related]

  • 7. Hemosiderosis in rodents and the effect of acetohydroxamic acid on urinary iron excretion.
    Corden BJ.
    Exp Hematol; 1986 Nov; 14(10):971-4. PubMed ID: 3770104
    [Abstract] [Full Text] [Related]

  • 8. An in vivo evaluation of iron-chelating drugs derived from pyridoxal and its analogs.
    Johnson DK, Pippard MJ, Murphy TB, Rose NJ.
    J Pharmacol Exp Ther; 1982 May; 221(2):399-403. PubMed ID: 7077535
    [Abstract] [Full Text] [Related]

  • 9. Iron retention and excretion in mice transfused with homologous or heterologous blood and treated with chelators.
    Gralla EJ, Burgess DH.
    Methods Find Exp Clin Pharmacol; 1982 May; 4(3):151-9. PubMed ID: 7121126
    [Abstract] [Full Text] [Related]

  • 10. Evaluation of iron-chelating agents in an in vivo system: potential usefulness of EHPG, a powerful iron-chelating drug.
    Hershko C, Grady RW, Link G.
    Br J Haematol; 1982 Jun; 51(2):251-60. PubMed ID: 7082583
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization.
    Hershko C, Grady RW, Cerami A.
    J Lab Clin Med; 1978 Aug; 92(2):144-51. PubMed ID: 681807
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
    Hershko C, Avramovici-Grisaru S, Link G, Gelfand L, Sarel S.
    J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
    [Abstract] [Full Text] [Related]

  • 13. Biological evaluation of some ionophore-polymeric chelator combinations for reducing iron overload.
    Tyson CA, LeValley SE, Chan R, Hobbs PD, Dawson MI.
    J Pharmacol Exp Ther; 1984 Mar; 228(3):676-81. PubMed ID: 6707917
    [Abstract] [Full Text] [Related]

  • 14. A new hydroxamate siderophore for iron supply of Salmonella.
    Rabsch W, Paul P, Reissbrodt R.
    Acta Microbiol Hung; 1987 Mar; 34(1):85-92. PubMed ID: 2957886
    [Abstract] [Full Text] [Related]

  • 15. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice.
    Kontoghiorghes GJ.
    Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144
    [Abstract] [Full Text] [Related]

  • 16. Mode of action of iron(III) chelators as antimalarials. III. Overadditive effects in the combined action of hydroxamate-based agents on in vitro growth of Plasmodium falciparum.
    Tsafack A, Golenser J, Libman J, Shanzer A, Cabantchik ZI.
    Mol Pharmacol; 1995 Feb; 47(2):403-9. PubMed ID: 7870051
    [Abstract] [Full Text] [Related]

  • 17. [The effects of various ligands on resorption, distribution and excretion of iron after oral administration].
    Forth W, Pfleger K, Rummel W, Seifen E, Richmond SI.
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1965 Dec 06; 252(3):242-57. PubMed ID: 4286718
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A new approach for potential combined chelation therapy using mono- and bis-hydroxypyridinones.
    Santos MA, Gama S, Gil M, Gano L.
    Hemoglobin; 2008 Dec 06; 32(1-2):147-56. PubMed ID: 18274992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.